Patents by Inventor Michael Imboden

Michael Imboden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11434259
    Abstract: The present invention relates to vaccine compositions and therapeutic interventions for treating and preventing infections and diseases caused by flaviviruses, including Zika, dengue, and Usutu virus. It also relates to compositions and methods for diagnosis and differential diagnosis of flaviviruses and co-endemic pathogens.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: September 6, 2022
    Assignee: IOGENETICS, LLC
    Inventors: Robert D. Bremel, Jane Homan, Michael Imboden
  • Publication number: 20200402615
    Abstract: The present invention provides methods and systems for identifying and classifying epitopes and use of that information to analyze proteins and peptides within proteins, especially potential epitopes, and to use the information to design synthetic peptides and proteins, analyze biopharmaceutical proteins, and diagnose autoimmune conditions. Peptides which are bound in MHC grooves comprise two sets of amino acids: those that face inwards into the groove and determine the binding affinity to the MHC molecule (the groove exposed motifs or GEM) and those which do not interact with the groove but rather are on the obverse side exposed outwardly to the T-cells (the T-cell exposed Motifs or TCEM). The present invention utilizes information related to the identity and physiochemical characteristics of the GEM and TCEM.
    Type: Application
    Filed: August 6, 2020
    Publication date: December 24, 2020
    Inventors: Robert D. Bremel, Jane Homan, Michael Imboden
  • Patent number: 10755801
    Abstract: The present invention provides methods and systems for identifying and classifying epitopes and use of that information to analyze proteins and peptides within proteins, especially potential epitopes, and to use the information to design synthetic peptides and proteins, analyze biopharmaceutical proteins, and diagnose autoimmune conditions. Peptides which are bound in MHC grooves comprise two sets of amino acids: those that face inwards into the groove and determine the binding affinity to the MHC molecule (the groove exposed motifs or GEM) and those which do not interact with the groove but rather are on the obverse side exposed outwardly to the T-cells (the T-cell exposed Motifs or TCEM). The present invention utilizes information related to the identity and physiochemical characteristics of the GEM and TCEM.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: August 25, 2020
    Assignee: IOGENETICS, LLC
    Inventors: Robert D. Bremel, Jane Homan, Michael Imboden
  • Publication number: 20190031722
    Abstract: The present invention relates to vaccine compositions and therapeutic interventions for treating and preventing infections and diseases caused by flaviviruses, including Zika dengue, and Usutu virus. It also relates to compositions and methods for diagnosis and differential diagnosis of flaviviruses and co-endemic pathogens.
    Type: Application
    Filed: January 25, 2017
    Publication date: January 31, 2019
    Inventors: Robert D. Bremel, Jane Homan, Michael Imboden
  • Publication number: 20170161430
    Abstract: The present invention provides methods and systems for identifying and classifying epitopes and use of that information to analyze proteins and peptides within proteins, especially potential epitopes, and to use the information to design synthetic peptides and proteins, analyze biopharmaceutical proteins, and diagnose autoimmune conditions. Peptides which are bound in MHC grooves comprise two sets of amino acids: those that face inwards into the groove and determine the binding affinity to the MHC molecule (the groove exposed motifs or GEM) and those which do not interact with the groove but rather are on the obverse side exposed outwardly to the T-cells (the T-cell exposed Motifs or TCEM). The present invention utilizes information related to the identity and physiochemical characteristics of the GEM and TCEM.
    Type: Application
    Filed: July 10, 2015
    Publication date: June 8, 2017
    Inventors: Robert D. Bremel, Jane Homan, Michael Imboden
  • Publication number: 20150284452
    Abstract: The present invention relates antimicrobial compositions, and in particular to antigen binding proteins comprising one or more domains that provide antimicrobial activity.
    Type: Application
    Filed: November 13, 2013
    Publication date: October 8, 2015
    Applicant: IOGENETICS, LLC
    Inventors: Robert Duane Bremel, Jane Homan, Michael Imboden, Brendan Keough
  • Patent number: 8703134
    Abstract: The present invention relates to fusion proteins comprising a microorganism targeting molecule (e.g., immunoglobulin) and a biocide. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in diverse fields.
    Type: Grant
    Filed: February 6, 2013
    Date of Patent: April 22, 2014
    Assignees: ioGenetics, LLC, Arizona Board of Regents on Behalf of the University of Arizona
    Inventors: Michael Imboden, Michael Riggs, Deborah A. Schaefer, Jane Homan, Robert D. Bremel
  • Publication number: 20130230516
    Abstract: The present invention relates to fusion proteins comprising a microorganism targeting molecule (e.g., immunoglobulin) and a biocide. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in diverse fields.
    Type: Application
    Filed: February 6, 2013
    Publication date: September 5, 2013
    Applicants: Arizona Board of Regents on behalf of the University of Arizona, ioGenetics, LLC
    Inventors: Michael Imboden, Michael Riggs, Deborah A. Schaefer, Jane Homan, Robert D. Bremel
  • Patent number: 8394379
    Abstract: The present invention relates to fusion proteins comprising a microorganism targeting molecule (e.g., immunoglobulin) and a biocide. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in diverse fields.
    Type: Grant
    Filed: January 13, 2010
    Date of Patent: March 12, 2013
    Assignee: ioGenetics, LLC
    Inventors: Michael Imboden, Michael Warren Riggs, Deborah A. Schaefer, Jane Homan
  • Patent number: 8222188
    Abstract: The present invention relates to the production of antibody libraries. In particular, the present invention relates to the use of integrating retroviral vectors to generate libraries comprising a plurality of combinations of antibody light chains and heavy chains. The present invention thus provides improved methods of generating and screening antibody libraries comprising large numbers of unique antibodies.
    Type: Grant
    Filed: June 29, 2009
    Date of Patent: July 17, 2012
    Assignee: Catalent Pharma Solutions, LLC
    Inventors: Robert D. Bremel, Kurt Eakle, Michael Imboden
  • Publication number: 20100183611
    Abstract: The present invention relates to fusion proteins comprising a microorganism targeting molecule (e.g., immunoglobulin) and a biocide. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in diverse fields.
    Type: Application
    Filed: January 13, 2010
    Publication date: July 22, 2010
    Applicants: IOGENETICS, LLC., ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
    Inventors: Michael Imboden, Michael Riggs, Deborah A. Schaefer, Jane Homan
  • Publication number: 20100111976
    Abstract: The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing).
    Type: Application
    Filed: September 24, 2009
    Publication date: May 6, 2010
    Applicant: IOGENETICS, LLC
    Inventors: Michael Imboden, Jane Homan, Robert D. Bremel
  • Publication number: 20100034824
    Abstract: The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzyme) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing).
    Type: Application
    Filed: August 5, 2009
    Publication date: February 11, 2010
    Applicants: IOGENETICS, LLC, THE ARIZONA BOARD OF REGENTS
    Inventors: Michael Imboden, Michael Riggs, Deborah A. Schaefer
  • Publication number: 20100009869
    Abstract: The present invention relates to the production of antibody libraries. In particular, the present invention relates to the use of integrating retroviral vectors to generate libraries comprising a plurality of combinations of antibody light chains and heavy chains. The present invention thus provides improved methods of generating and screening antibody libraries comprising large numbers of unique antibodies.
    Type: Application
    Filed: June 29, 2009
    Publication date: January 14, 2010
    Inventors: Robert D. Bremel, Kurt Eakle, Michael Imboden
  • Patent number: 7566447
    Abstract: The present invention relates to the use of biocide (e.g., bactericidal enzyme) to target pathogens. In particular, the present invention provides biocides for use in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., water purification).
    Type: Grant
    Filed: October 20, 2005
    Date of Patent: July 28, 2009
    Assignees: Iogenetics, LLC, The Arizona Board of Regents on Behalf of the University of Arizona
    Inventors: Jane Homan, Michael Imboden, Michael Riggs, Stephane Carryn, Deborah A. Schaefer
  • Publication number: 20090098121
    Abstract: The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing).
    Type: Application
    Filed: October 19, 2007
    Publication date: April 16, 2009
    Applicant: ioGenetics, LLC
    Inventors: Michael Imboden, Jane Homan, Robert D. Bremel
  • Publication number: 20080274095
    Abstract: The present invention relates to the use of biocide (e.g., bactericidal enzyme) to target pathogens. In particular, the present invention provides biocides for use in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., water purification).
    Type: Application
    Filed: October 19, 2005
    Publication date: November 6, 2008
    Inventors: Jane Homan, Michael Imboden, Michael W. Riggs, Stephane Carryn
  • Publication number: 20080267943
    Abstract: The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing).
    Type: Application
    Filed: October 19, 2007
    Publication date: October 30, 2008
    Applicant: ioGenetics, LLC
    Inventors: Michael Imboden, Jane Homan, Robert D. Bremel
  • Publication number: 20080269122
    Abstract: The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing).
    Type: Application
    Filed: October 19, 2007
    Publication date: October 30, 2008
    Applicant: ioGenetics, LLC
    Inventors: Michael Imboden, Jane Homan, Robert D. Bremel
  • Patent number: 7384738
    Abstract: The present invention relates to the expression and screening of genomic DNA sequences encoding uncharacterized genes and proteins. The present invention provides systems utilizing unique features of retroviral replication to analyze uncharacterized genes derived from genomic DNA samples. In preferred embodiments, a segment of genomic DNA is inserted between 5? and 3? viral long terminal repeats (LTRs) in a vector (e.g., a plasmid, cosmid, or artificial chromosome vector). The resulting vector (or library of vectors containing a plurality of independent genomic sequences) is then introduced into a retroviral packaging cell. The resulting provirus or proteins expression from the provirus are then analyzed.
    Type: Grant
    Filed: March 26, 2003
    Date of Patent: June 10, 2008
    Inventors: Robert D. Bremel, Gregory T. Bleck, Michael Imboden, Kurt Eakle